Sheffield Teaching Hospitals NHS Foundation Trust

Running trials

• Recruiting

  Efficacy of Symprove Probiotics in Coeliac Disease

  NCT07360106· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Recruiting

  Virtual Dietetic Interventions in Patients With Coeliac

  NCT07172555· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Recruiting

  A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

  NCT07206225· Phase 1· Pfizer· Source

• Recruiting

  The Use of Advanced Imaging in HFpEF

  NCT06905405· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  NCT06976203· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

  NCT06735248· Phase 2· ModernaTX, Inc.· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  The U.K. NorthStar Clinical Network

  NCT06711692· University College, London· Source

• Recruiting

  Developing the Probability Algorithm for Pulmonary Hypertension Echocardiography

  NCT06386185· Royal United Hospitals Bath NHS Foundation Trust· Source

• Recruiting

  Transcutaneous Vagus Nerve Stimulation in Aphasia After Stroke

  NCT06403475· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

  NCT05789758· Biogen· Source

• Recruiting

  Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

  NCT05866419· Alcyone Therapeutics, Inc· Source

• Active, not recruiting

  Improving Pulmonary Hypertension Screening by Echocardiography

  NCT06038149· Royal United Hospitals Bath NHS Foundation Trust· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Recruiting

  Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

  NCT05848765· Phase 2· University of Birmingham· Source

• Recruiting

  Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation

  NCT06195800· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Weill Medical College of Cornell University· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

  NCT06511648· Phase 2· Spanish Oncology Genito-Urinary Group· Source

• Recruiting

  FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

  NCT05614739· Phase 1· Eli Lilly and Company· Source

• Recruiting

  UK Heart Failure With Preserved Ejection Fraction

  NCT05441839· Manchester University NHS Foundation Trust· Source

• Recruiting

  Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT

  NCT05613023· Phase 3· Institute of Cancer Research, United Kingdom· Source

• Recruiting

  Adult SMA Research and Clinical Hub

  NCT06978985· Newcastle-upon-Tyne Hospitals NHS Trust· Source

• Active, not recruiting

  Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

  NCT05315258· Phase 2· University of Oxford· Source

• Recruiting

  A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT05085028· Phase 3· Imperial College London· Source

• Recruiting

  Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

  NCT05329532· Phase 1/2· Scancell Ltd· Source

• Recruiting

  Awareness Detection and Communication in Disorders of Consciousness

  NCT03827187· University of Ulster· Source

• Active, not recruiting

  A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling

  NCT04936620· St George's, University of London· Source

• Active, not recruiting

  A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

  NCT04969835· Phase 1· Avacta Life Sciences Ltd· Source

• Recruiting

  Ex VIvo DEtermiNed Cancer Therapy

  NCT05231655· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Active, not recruiting

  ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

  NCT04695080· Phase 2/3· Queen Mary University of London· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Active, not recruiting

  Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus

  NCT04046133· Phase 1· Cardiff University· Source

• Recruiting

  Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

  NCT04302870· Phase 2/3· University of Edinburgh· Source

• Recruiting

  Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension (FIT-PH)

  NCT04078243· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Active, not recruiting

  Paediatric Sjögren Syndrome Cohort Study and Repository (PaedSSCoRe)

  NCT04762108· University College, London· Source

• Recruiting

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  NCT04045665· Phase 3· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Recruiting

  ICONIC: Improving Outcomes Through Collaboration in OsteosarComa

  NCT04132895· University College, London· Source

• Active, not recruiting

  Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease

  NCT03305250· University Hospital Birmingham NHS Foundation Trust· Source

• Active, not recruiting

  SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

  NCT04079166· Phase 2· Scancell Ltd· Source

• Active, not recruiting

  A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

  NCT03821610· Phase 2· University of Birmingham· Source

• Active, not recruiting

  A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

  NCT03539744· Phase 3· AbbVie· Source

• Active, not recruiting

  EPA for Metastasis Trial 2

  NCT03428477· Phase 3· Mark A Hull, PhD FRCP· Source

• Active, not recruiting

  Evaluating the Effects of Frozen Section Technology on Oncological and Functional Outcomes at Radical Prostatectomy.

  NCT03317990· University College, London· Source

• Active, not recruiting

  IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

  NCT03194815· Phase 2· University of Cambridge· Source

Showing 50 of 54.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer4 recruiting
• Spinal muscular atrophy3 recruiting
• Childhood cancers2 recruiting
• Coeliac disease2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Kidney cancer2 recruiting
• Multiple sclerosis2 recruiting
• Prostate cancer2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Sarcoma2 recruiting
• Stroke2 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Spinal cord injury1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Ii-HANC Improving Incurable Head and Neck Cancer Healthcare Experiences

  NCT05714436· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Completed

  Bolus Pouch Feed Study

  NCT05822557· Nutricia UK Ltd· Source

• Completed

  Virtual Peer-to-peer Support Programme for Carers of MND

  NCT04695210· King's College London· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?

  NCT04990791· Phase 4· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Recruiting

  Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole

  NCT04965298· Phase 3· Norfolk and Norwich University Hospitals NHS Foundation Trust· Source

• Completed

  PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

  NCT04870333· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source

• Completed

  Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

  NCT04464434· Phase 4· UMC Utrecht· Source

• Terminated

  EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04437368· Phase 2· Gyroscope Therapeutics Limited· Source

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Population Health Research Institute· Source

• Completed

  Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

  NCT02461888· Phase 2· University of Leeds· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Canadian Cancer Trials Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• ALS (motor neurone disease)28 works · 2 trials
• Coeliac disease19 works · 2 trials
• Pulmonary arterial hypertension17 works · 3 trials
• Irritable bowel syndrome11 works · 0 trials
• Myasthenia gravis9 works · 1 trial
• Mesothelioma8 works · 0 trials
• Spinal muscular atrophy6 works · 3 trials
• Gastroparesis5 works · 0 trials